KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Gains from Investment Securities: 2010-2024

Historic Gains from Investment Securities for Sarepta Therapeutics (SRPT) over the last 15 years, with Dec 2024 value amounting to $8.9 million.

  • Sarepta Therapeutics' Gains from Investment Securities rose 73.51% to -$1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $30.1 million, marking a year-over-year increase of 0.99%. This contributed to the annual value of $8.9 million for FY2024, which is 7.29% down from last year.
  • Per Sarepta Therapeutics' latest filing, its Gains from Investment Securities stood at $8.9 million for FY2024, which was down 7.29% from $9.6 million recorded in FY2023.
  • Sarepta Therapeutics' Gains from Investment Securities' 5-year high stood at $9.6 million during FY2023, with a 5-year trough of $7.8 million in FY2020.
  • Its 3-year average for Gains from Investment Securities is $9.2 million, with a median of $9.1 million in 2022.
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first grew by 11.38% in 2022, then declined by 7.29% in 2024.
  • Yearly analysis of 5 years shows Sarepta Therapeutics' Gains from Investment Securities stood at $7.8 million in 2020, then rose by 4.49% to $8.2 million in 2021, then grew by 11.38% to $9.1 million in 2022, then increased by 4.96% to $9.6 million in 2023, then dropped by 7.29% to $8.9 million in 2024.